Taking full advantage of the stock market and investing with confidence are common goals for new and old investors alike.
Achieving those goals is made easier with the Zacks Style Scores, a unique set of guidelines that rates stocks based on popular investing methodologies, namely value, growth, and momentum. The Style Scores can help you narrow down which stocks are better for your portfolio and which ones can beat the market over the long-term.
Momentum investors, who live by the saying “the trend is your friend,” are most interested in taking advantage of upward or downward trends in a stock’s price or earnings outlook. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks.
San Diego, CA-based Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing innovative medicines to address unmet medical needs in CNS disorders and rare diseases.
ACAD boasts a Momentum Style Score of A and VGM Score of B, and holds a Zacks Rank #3 (Hold) rating. Shares of Acadia Pharmaceuticals has seen some interesting price action recently; the stock is up 0.4% over the past one week and up 13.6% over the past four weeks. And in the last one-year period, ACAD has lost 27.3%. As for the stock’s trading volume, 1,411,856.25 shares on average were traded over the last 20 days.
A company’s earnings performance is important for momentum investors as well. For fiscal 2024, six analysts revised their earnings estimate higher in the last 60 days for ACAD, while the Zacks Consensus Estimate has increased $0.19 to $0.73 per share. ACAD also boasts an average earnings surprise of 54.1%.
ACAD should be on investors’ short list because of its impressive earnings fundamentals, a good Zacks Rank, and strong Momentum and VGM Style Scores.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report
To read this article on Zacks.com click here.
This article was originally published here.
